Silverleafe Capital Partners LLC Takes Position in Natera, Inc. (NASDAQ:NTRA)

Silverleafe Capital Partners LLC bought a new position in shares of Natera, Inc. (NASDAQ:NTRA) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 3,984 shares of the medical research company’s stock, valued at approximately $631,000.

Several other large investors have also added to or reduced their stakes in NTRA. Itau Unibanco Holding S.A. bought a new position in shares of Natera during the 2nd quarter worth approximately $28,000. Quarry LP lifted its position in shares of Natera by 148.4% during the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 190 shares during the period. Versant Capital Management Inc boosted its stake in Natera by 345.8% during the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after acquiring an additional 166 shares in the last quarter. Covestor Ltd grew its holdings in Natera by 34.3% in the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after purchasing an additional 95 shares during the period. Finally, GAMMA Investing LLC increased its stake in Natera by 32.7% in the third quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 106 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insider Buying and Selling at Natera

In other news, CFO Michael Burkes Brophy sold 608 shares of Natera stock in a transaction on Monday, October 21st. The stock was sold at an average price of $120.76, for a total value of $73,422.08. Following the completion of the transaction, the chief financial officer now directly owns 74,014 shares in the company, valued at approximately $8,937,930.64. The trade was a 0.81 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Steven Leonard Chapman sold 1,709 shares of the firm’s stock in a transaction dated Monday, October 21st. The stock was sold at an average price of $120.76, for a total value of $206,378.84. Following the completion of the transaction, the chief executive officer now owns 194,615 shares of the company’s stock, valued at approximately $23,501,707.40. This represents a 0.87 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 127,932 shares of company stock valued at $20,635,430. Company insiders own 7.60% of the company’s stock.

Natera Stock Performance

Shares of Natera stock traded up $3.68 during trading hours on Monday, hitting $171.28. 536,181 shares of the company’s stock traded hands, compared to its average volume of 803,790. The stock has a market capitalization of $22.61 billion, a price-to-earnings ratio of -97.32 and a beta of 1.65. Natera, Inc. has a 12-month low of $59.80 and a 12-month high of $175.63. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The company has a fifty day simple moving average of $155.07 and a 200-day simple moving average of $129.99.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business had revenue of $439.80 million during the quarter, compared to the consensus estimate of $361.43 million. During the same quarter last year, the company posted ($0.95) earnings per share. The firm’s quarterly revenue was up 63.9% compared to the same quarter last year. Equities research analysts anticipate that Natera, Inc. will post -1.61 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently commented on the company. JPMorgan Chase & Co. raised their target price on Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, December 13th. TD Cowen raised their price objective on Natera from $155.00 to $175.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Leerink Partners upped their target price on Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. StockNews.com cut Natera from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. Finally, Canaccord Genuity Group boosted their price target on shares of Natera from $165.00 to $180.00 and gave the company a “buy” rating in a research note on Friday. One equities research analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat, Natera presently has an average rating of “Moderate Buy” and a consensus target price of $153.67.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.